Email
Print
Gastroesophageal Junction Carcinoma Treatment Market - Forecast(2024 - 2030)
Gastroesophageal Junction Carcinoma Treatment Market Overview
The Gastroesophageal Junction Carcinoma Treatment Market Size is estimated to reach $2.6 billion by 2028 and it is poised to grow at a CAGR of 10.5% over the forecast period of 2023-2028. Gastroesophageal Junction Cancer develops in between the food pipe and stomach. This form of cancer is also known as esophagus gastric junctional cancer or esophageal adenocarcinoma. The symptoms of this form of cancer are chest pain, fatigue, heartburn, indigestion and dysphagia. Critically, an increased incidence of obesity and GERD leads to an increased case of Gastroesophageal Junction Carcinoma. The World Obesity Atlas 2022, published by the World Obesity Federation, predicts that one billion people globally, including 1 in 5 women and 1 in 7 men, would be living with obesity by 2030. Profound treatment methods are available. Also, strong research and clinical trials for newer methodologies are in place that would aid the treatment market. This is the overall Gastroesophageal Junction Carcinoma Treatment industry outlook for the projected period of 2023-2028.
Gastroesophageal Junction
Carcinoma Treatment Market Report Coverage
The report: “Gastroesophageal Junction Carcinoma Treatment Market Forecast (2023-2028)" by IndustryARC, covers an in-depth
analysis of the following segments in the Gastroesophageal Junction Carcinoma
Treatment Market.
Key Takeaways
- Geographically, Asia-Pacific held a dominant market share in 2022. It is owing to a higher prevalence and incidence of this form of cancer in the eastern and southern parts of the regions. However, North America is expected to offer lucrative growth opportunities over the forecast period of 2023-2028 due to the increasing population of at-risk patients.
- The rowing cases of obesity and substandard living patterns in LMIC countries assisted by the significant prevalence of GERD symptoms and disease boost market growth. However, high cancer treatment costs and late detection levels impede market growth.
- A detailed analysis of strengths, weaknesses, opportunities and threats would be provided in the Gastroesophageal Junction Carcinoma Treatment Market Report.
Gastroesophageal Junction Carcinoma Treatment Market - Market Share (%) by region, 2022.
For More Details on This Report - Request for Sample
Gastroesophageal Junction Carcinoma Treatment Market Segment Analysis - by Cancer Type
The Gastroesophageal Junction Carcinoma Treatment Market can be
further segmented into type 1, type 2 and type 3. Type 1 held a dominant
market share in 2022. This form of cancer has a high resemblance
to esophageal cancer. Barrett’s esophagus increases the risk of
forming a GOJ type-1 cancer. In this condition, the cell
lining of the esophagus becomes highly abnormal much like squamous cell carcinoma.
Moreover, the condition can occur from long-term acid reflux, indigestion,
chest pain, dysphagia and others. As per Cleveland Clinic 2019, nearly 20% of
the U.S. population suffers from chronic acid reflux. However, the type-3 form of
GOJ is estimated to be the fastest-growing one, with a CAGR of 11.2% over the
forecast period of 2023-2028. This form of cancer spreads up into the GEJ
from the stomach/gastric region. Additionally, the cancer is usually 3-5
centimeters in length.
Gastroesophageal Junction Carcinoma Treatment Market Segment Analysis - by Treatment
The Gastroesophageal Junction Carcinoma Treatment Market based
on treatment can be further segmented into Surgery, Radiotherapy, Chemotherapy,
Chemoradiotherapy and Immunotherapy. Chemoradiotherapy held a dominant market
share in 2022. This form of the treatment plan is generally preferred before the surgery, in cases where cancer hasn’t spread and the tumor
region isn’t affecting the mortality. By opting for this form of
treatment option, drugs of both chemotherapy and radiotherapy are combined to
increase effectiveness. As per CDC, nearly 650,000 patients receive
chemotherapy each year in the U.S. However, immunotherapy is estimated to be
the fastest-growing segment, with a CAGR of 12.6% over the forecast period of
2023-2028. Additionally, immunotherapy boosts the body’s immune system to destroy cancer.
Gastroesophageal Junction Carcinoma Treatment Market Segment Analysis - by Geography
Asia-Pacific held a dominant market share of 39% in 2022. It is due to the significant prevalence of this cancer type in the eastern part of Asia-Pacific. As per Globocon 2020, the incidence in Asia in 2020 was nearly 79.7% of the entire world for esophagus form of cancer, which includes GEJ as well. Critically, the incidence of this form of cancer runs high as well in the region. However, North America is expected to offer lucrative growth opportunities over the forecast period of 2023-2028. It is owing to a significant rise in obesity cases, which propels the incidence of GEJ.
Gastroesophageal Junction Carcinoma Treatment Market Drivers
Significant Increase in Obesity-related Cases:
Various cross-sectional studies performed by researchers
across the globe have suggested close ties between obesity and gastroesophageal
junction cancer. Furthermore, such claims have been proven right with a higher incidence of this cancer type in males and a higher prevalence of
obesity in males in comparison to females across the regions. As per NCBI
findings, the risk for cancer is 2x-3x more in people who are obese than
simply overweight. As per CDC, the U.S. obesity prevalence was 41.9% from
2017-2020. Some of the common reasons that link close ties between obesity and
esophageal adenocarcinoma are altered intestinal
microbiome, metabolic syndrome and the low-grade inflammation induced
by obesity. Lastly, obesity and the
secretion of mediators by adipocytes may directly influence the
esophageal epithelium, increasing the cancer risk.
Aging Population Supplemented by GERD:
A high correlation has been established by various researchers between three anomalies - senior age, GERD and esophageal junction cancer. GERD chronic gastro-esophageal reflux disease becomes extremely normal in the senior population due to the sedentary lifestyle of the population. Moreover, the senior population often does not have controlled BMIs or is obese which further contributes to the alleviation of the condition. Also, aggressive GERD-like symptoms often translate into a higher risk of Gastroesophageal Junction Carcinoma and often go unnoticed. Lastly, a fast-growing aging population across the world assists in the increment of esophageal cancer cases. As per OECD, nearly 10% of the world population is senior/old in 2020.
Gastroesophageal Junction Carcinoma Treatment Market Challenges
Low Treatment Coverage across Developing Regions along with the High Cost of Drugs for Esophageal Junction Cancer:
As per NCBI 2019, only 1 in 5 or 20% of patients suffering
from any form of cancer receives curative treatment in the LMIC setting of Central
America. Moreover, the same institute predicts that by 2030, 70% of the cancer
burden would occur in LMIC settings and be driven by 7 major forms of cancer,
including esophageal cancer as a major propeller. Furthermore, as per Science
Direct 2021, unemployed patients have spent significantly more time between
diagnosis and cancer treatment. The aftermath of the pandemic along
with the rising threat of a recession would mitigate treatment
offerings. Additionally, the cost associated with the treatment of following cancer hampers the growth of the market.
Gastroesophageal Junction Carcinoma Treatment Industry Outlook
Product launches, mergers and acquisitions, joint ventures and
geographical expansions are key strategies adopted by players in the Gastroesophageal
Junction Carcinoma Treatment Industry. The top 10 companies in the Gastroesophageal
Junction Carcinoma Treatment Market are:
- Astellas Pharma
- BAYER AG
- BeiGene Ltd
- Boston Biomedical Inc
- Bristol-Myers Squibb Company
- Celgene Corporation
- Gilead Sciences
- Merck and Co
- Pfizer Inc
- Ono Pharmaceuticals
Recent Developments
- In October 2022, HUTCHMED China announced the initiation of Phase II and III trials of fruquintinib in combination with sintillimab as a second-line treatment of gastric cancer and esophageal junction cancer.
Relevant Titles
Report Code: HCR 0078
Report Code: HCR 0194
Report Code: HCR 0196
For more Lifesciences and Healthcare Market reports, please click here